Skip to main content

Coronavirus (COVID-19) Updates: Visitation Policies (New! 11.25.20) | How We're Keeping You Safe | Latest COVID Information

Coronavirus (COVID-19): Visitor Restrictions, Resources, and Updates

Explore URMC
menu
URMC / Research / Clinical Trials / Study Details

ULYM17025 / ILyAD / Jonathan Friedberg

Research Question:
Can modification of vitamin D levels in the blood, through supplementation, improve outcomes in patients with indolent lymphoma treated with rituximab?

Basic Study Information

Purpose:
Despite strong evidence suggesting that vitamin D deficiency is associated with undesirable outcomes in patients with numerous cancers, there has never been a thorough study of vitamin D treatment in subjects undergoing treatment for cancer. The purpose of this study is to evaluate whether modification of vitamin D levels in the blood, through supplementation, can improve outcomes.

Location: Cancer Center
Study Web URL:  https://clinicaltrials.gov/ct2/show/NCT03078855?term=ilyad&rank=1
Study Reference #: ULYM17025

Lead Researcher (Principal Investigator)

Lead Researcher:  Jonathan Friedberg, MD

Study Contact Information

Study Coordinator: Amber Johnson
Email: amber_johnson@urmc.rochester.edu

Additional Study Details

Learn More About These Conditions

More information about Lymphoma

Return to Search